AAS
KRYS icon

Ameritas Advisory Services’s Krystal Biotech KRYS Stock Holding History

Ameritas Advisory Services’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$258 – 2064
2026
Q1 		$258 Buy
+1
New +$266 ﹤0.01% 1043

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ameritas Advisory Services's KRYS Position: Q2 2026 in Review

Ameritas Advisory Services sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 1 share — an estimated $258 sold.

Ameritas Advisory Services first reported a position in KRYS in Q1 2026 and held it in 1 quarter. The position peaked at $258 in Q1 2026. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Ameritas Advisory Services reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • Ameritas Advisory Services sold 1 Krystal Biotech share in Q2 2026, an estimated $258.
  • Ameritas Advisory Services first reported a position in Krystal Biotech in Q1 2026 and held it in 1 quarter.
  • Ameritas Advisory Services's Krystal Biotech position peaked at $258 in Q1 2026.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.